Evidence map›Paper›PMID 27068811›Full record

ArticleLipids in health and disease2016

Plasma lipid profiling of different types of hepatic fibrosis induced by carbon tetrachloride and lomustine in rats.

Masaki Ishikawa, Kosuke Saito, Hiroshi Yamada, Noriyuki Nakatsu, Keiko Maekawa, Yoshiro Saito

Open access · goldAbstract read
In one paragraph

Article in Lipids in health and disease, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.4field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 18 citations in OpenAlex.

  1. Hepatocyte-SpecificDiabetes, metabolic syndrome and obesity : targets and therapy · 2024
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Masaki IshikawaDivision of Medical Safety Science, National Institute of Health Sciences, 1-18-1 Kamiyoga, Setagaya, Tokyo, 158-8501, Japan.
Kosuke SaitoDivision of Medical Safety Science, National Institute of Health Sciences, 1-18-1 Kamiyoga, Setagaya, Tokyo, 158-8501, Japan. saitok2@nihs.go.jp.
Hiroshi YamadaToxicogenomics Informatics Project, National Institutes of Biomedical Innovation, Health and Nutrition, 7-6-8 Saitoazagi, Ibaraki, Osaka, 567-0085, Japan.
Noriyuki NakatsuToxicogenomics Informatics Project, National Institutes of Biomedical Innovation, Health and Nutrition, 7-6-8 Saitoazagi, Ibaraki, Osaka, 567-0085, Japan.
Keiko MaekawaDivision of Medical Safety Science, National Institute of Health Sciences, 1-18-1 Kamiyoga, Setagaya, Tokyo, 158-8501, Japan.
Yoshiro SaitoDivision of Medical Safety Science, National Institute of Health Sciences, 1-18-1 Kamiyoga, Setagaya, Tokyo, 158-8501, Japan.
National Institute of Health Sciences · JPNational Institute of Biomedical Innovation, Health and Nutrition · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPlasma lipid profiling has emerged as a useful tool for understanding the pathophysiology of hepatic injury and disease. Hepatic fibrosis results from chronic, progressive damage to the liver and can lead, in turn, to more serious conditions such as hepatic cirrhosis and hepatocellular carcinoma. Thus, the present study aimed to investigate the plasma lipid profiles of two types of hepatic fibrosis in order to aid the understanding of the pathophysiology of hepatic fibrosis.

methodsA liquid chromatography and mass spectrometry platform was used to reveal and compare the plasma lipid profiles of two types of chemical-induced hepatic fibrosis. Rat models of centrilobular fibrosis and bile duct fibrosis were established via chronic exposure to the known fibrogenic hepatotoxins, carbon tetrachloride (CCl4) or lomustine (LS), respectively, over a 28-day period. To delineate the specific alterations in the lipid profiles as a result of the hepatic fibrosis, we also employed non-fibrogenic hepatotoxicants (2-acetamidofluorene, N-nitrosodiethylamine, and ethambutol) as well as 3-day treatment of CCl4 and LS, which did not induce fibrosis.

resultsOur assay platform identified 228 lipids in the rat plasma, and the global lipid profile clearly distinguished these models from the control via principal component analysis. In addition, the alteration of the plasma lipid profile caused by CCl4 and LS were clearly different. Furthermore, a number of lipids were identified as specific alterations caused by fibrosis induced only by CCl4 and LS, respectively. Three lysophosphatidylcholines (LPC[18:3], LPC[20:4], and LPC[22:6]), and three phosphatidylcholines (PC[18:2/20:4], PC[40:8], and PC[20:4/22:6]) are specific circulating lipids, the levels of which were altered by both CCl4 and LS treatment; however, their levels were decreased by chronic exposure to CCl4 and increased by chronic exposure to LS.

conclusionsThese results suggest that different types of chemical-induced hepatic fibrosis demonstrate clear differences in their plasma lipid profiles. Our study provides insights into the alteration of plasma lipidomic profiles as a result of the fibrosis of different parts of the hepatic lobule, and may help to understand the pathophysiology of different types of hepatic fibrosis.

Indexed as

AnimalsCarbon TetrachlorideLipidsLiverLiver CirrhosisLomustineMaleRats, Sprague-DawleyCarbon TetrachlorideLipidsLomustineHepatic fibrosisHepatotoxicityLC/MS, lipidomicsPlasma lipid profiling

Identifiers

PMID27068811
PMCPMC4828842
OpenAlexW2336669281

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.